Clinical Trial

Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis

Study acronym: RAPA-4-PAF
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The hypothesize of this research is that rapamycin is effective and well-tolerated in teenagers with familial adenomatous polyposis (FAP). Rapamycin could be effective in blocking the formation of adenomas and/or their evolution by decreasing their size and number. Researchers aim to assess the safety profile of rapamycin in FAP adolescents using a 2 low dose regimen.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-08; most recent amendment 2026-05-04.
Trial Details
NCT Number NCT06308445
Lead Sponsor University Hospital, Toulouse
Conditions Familial Adenomatous Polyposis
Enrollment 25 participants
Start Date 2026-09-01
Primary Completion 2030-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-08